Abbott secures FDA clearance for two over-the-counter glucose monitors
Adds analyst comment in paragraphs 4 and 8, shares in paragraph 10
By Pratik Jain and Sriparna Roy
June 10 (Reuters) -Abbott Laboratories ABT.N said on Monday the U.S. health regulator had cleared the company's two new over-the-counter glucose monitoring devices, expanding its presence in a fast-growing, multi-billion-dollar market.
The devices, one for the health-conscious and another for those with diabetes, follow the company's FreeStyle Libre, which generates over $1 billion every quarter and is sold under prescription for patients with diabetes.
One of the new OTC devices, Libre Rio, targets people with type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
The Food and Drug Administration's clearance for Libre Rio allows access to a continuous glucose monitor for 24.5 million type 2 diabetes patients who do not use insulin, RBC Capital Markets analyst Shagun Singh said.
The other product, Lingo, will help to track glucose and provide personalized insights to improve overall well-being.
Abbott plans to launch Lingo this summer, a spokesperson said, without disclosing details on pricing. The company said it would share details on pricing and availability of Libre Rio later.
Lingo is available in Britain since January for 120-150 pounds ($152-$190) per month.
Abbott believes the new devices combined can be at least a $1 billion plus in annual sales opportunity as a first stop, the RBC analyst said.
Libre Rio and Lingo will compete with Dexcom's DXCM.O Stelo, which in March became the first continuous glucose monitor to be approved by the FDA for OTC sales.
Shares of Abbott were up about 1% in morning trade.
Olympic athletes turn to diabetes tech in pursuit of medals https://www.reuters.com/sports/olympics/olympic-athletes-turn-diabetes-tech-pursuit-medals-2024-06-10/
Reporting by Sriparna Roy and Pratik Jain in Bengaluru; Editing by Shailesh Kuber and Maju Samuel
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
